CITED2 is a novel direct effector of peroxisome proliferator-activated receptor γ in suppressing hepatocellular carcinoma cell growth

Cancer

Volumn 119, Issue 6, 2013, Pages 1217-1226

  Cheung, Kin Fai ^a   Zhao, Junhong ^a   Hao, Ying ^b   Li, Xiaoxing ^a   Lowe, Anson W ^b   Cheng, Alfred S L ^a   Sung, Joseph J Y ^a   Yu, Jun ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; CITED2; hepatocellular carcinoma; peroxisome profilerator activating receptor gamma; proliferation

Indexed keywords

ADENOVIRUS VECTOR; ALPHA1 INTERFERON; ANTINEOPLASTIC AGENT; CASPASE 8; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTOKINE RECEPTOR; DEATH RECEPTOR 3; GELATINASE A; GRANZYME A; MASPIN; MESSENGER RNA; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN CITED2; PROTEIN TNFRSF1A; ROSIGLITAZONE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL STRAIN HEPG2; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CLONOGENESIS; DOWNSTREAM PROCESSING; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; PPAR GAMMA; REPRESSOR PROTEINS; THIAZOLIDINEDIONES; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84874743183     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27865     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
2. Duffy A, Greten T,. Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2010; 4: 551-560.
3. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005; 97: 1532-1538.
4. Garcia-Bates TM, Bernstein SH, Phipps RP,. Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin Cancer Res. 2008; 14: 6414-6425.
5. Michalik L, Desvergne B, Wahli W,. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004; 4: 61-70.
6. Koeffler HP,. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003; 9: 1-9.
7. Galli A, Ceni E, Mello T, et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology. 2010; 52: 493-505.
8. Koga H, Harada M, Ohtsubo M, et al. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology. 2003; 37: 1086-1096.
9. Yu J, Shen B, Chu ES, et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology. 2010; 51: 2008-2019.
10. Sherlock G, Hernandez-Boussard T, Kasarskis A, et al. The Stanford Microarray Database. Nucleic Acids Res. 2001; 29: 152-155.
11. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98: 5116-5121.
12. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology. 2006; 43: 134-143.
13. Weng JR, Chen CY, Pinzone JJ, et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer. 2006; 13: 401-413.
14. Qu X, Lam E, Doughman YQ, et al. Cited2, a coactivator of HNF4alpha, is essential for liver development. EMBO J. 2007; 26: 4445-4456.
15. Yokota H, Goldring MB, Sun HB,. CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear. J Biol Chem. 2003; 278: 47275-47280.
16. Bai L, Merchant JL,. A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Lett. 2007; 581: 5904-5910.
17. Sherr CJ,. Cancer cell cycles. Science. 1996; 274: 1672-1677.
18. Alao JP,. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007; 6: 24.
19. De Palma M, Mazzieri R, Politi LS, et al. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell. 2008; 14: 299-311.
20. Walczak H, Haas TL,. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol Biol. 2008; 414: 221-239.
21. Bertsch U, Edelmann B, Tchikov V, Winoto-Morbach S, Schütze S,. Compartmentalization of TNF-receptor 1 signaling: TNF-R1-associated caspase-8 mediates activation of acid sphingomyelinase in late endosomes. Adv Exp Med Biol. 2011; 691: 605-616.
22. UM, Shen L, Oshida T, Miyauchi J, Yamada M, Miyashita T,. Identification of novel direct transcriptional targets of glucocorticoid receptor. Leukemia. 2004; 18: 1850-1856.
23. Wong KK, Maser RS, Bachoo RM, et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature. 2003; 421: 643-648.
24. Mardin WA, Petrov KO, Enns A, Senninger N, Haier J, Mees ST,. SERPINB5 and AKAP12-expression and promoter methylation of metastasis suppressor genes in pancreatic ductal adenocarcinoma. BMC Cancer. 2010; 10: 549.
25. Shi HY, Liang R, Templeton NS, et al. Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol Ther. 2002; 5: 755-761.
26. Teoh SS, Whisstock JC, Bird PI,. Maspin (SERPINB5) is an obligate intracellular serpin. J Biol Chem. 2010; 285: 10862-10869.
27. Greenberg RA, O'Hagan RC, Deng H, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene. 1999; 18: 1219-1226.
28. Li HC, Cao DC, Liu Y, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004; 88: 75-85.
29. Rojiani MV, Alidina J, Esposito N, et al. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010; 3: 775-781.
30. Wong JC, Chan SK, Schaeffer DF, et al. Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer. Clin Cancer Res. 2011; 17: 4167-4176.